All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Arexvy receives European approval expansion for respiratory syncytial virus prevention in all adults 18 and older
Vaccine, infectious disease, recombinant vaccine, RSV, adjuvanted vaccine, respiratory syncytial virus - Read more

Russian Ministry of Health approves Nanolek's Cegardex human papillomavirus vaccine for children aged 9-17 following Ph3 results
Vaccine, infectious disease, HPV vaccine, cervical cancer, pediatric population - Read more

THE GOOD
Business Development & Partnerships

HanchorBio, WuXi Biologics partner on strategic collaboration for bi- and multi-functional fusion protein development
Strategic partnership, oncology, autoimmune, fusion proteins, manufacturing, biologics development - Read more

Genyro licenses Caltech's “Sidewinder” DNA construction technology for breakthrough long sequence assembly capabilities
Licensing deal, DNA construction technology, gene therapy, biotechnology platform - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Sarepta Therapeutics' Elevidys gene therapy shows sustained benefits three years post-treatment in Ph3 Duchenne muscular dystrophy trial
Gene therapy, neurological, AAV gene therapy, Duchenne muscular dystrophy, liver toxicity - Read more

Mesoblast's Ryoncil (remestemcel-L-rknd) shows 84% survival rate in real-world pediatric steroid-refractory acute graft-versus-host disease
Cell therapy, autoimmune, mesenchymal stromal cells, graft-versus-host disease, pediatric population, steroid-refractory - Read more

United Therapeutics reports positive Ph1 results for miroliverELAP external liver assist in acute liver failure
Organ therapy, liver disease, bioengineered organ, acute liver failure, external liver assist - Read more

THE GOOD
Company Launches

Fortitude Biomedicines launches with $13M seed to combine molecular glues with ADCs for next-generation cancer and autoimmune therapies
Cancer, antibody-drug conjugates, protein degradation, platform technology, autoimmune - Read more

THE GOOD
Fundraises

Helix Acquisition Corp. III raises $150M SPAC IPO, healthcare-focused acquisition vehicle
Investment management, biotech investor, SPAC, healthcare services - Read more

1stBio Therapeutics raises $22M Series D for HPK1 inhibitor clinical development
Oncology, small molecule, HPK1 inhibitor, clinical-stage - Read more

THE GOOD
Investments

Recipharm debuts new Bengaluru facility for beta-lactam drugs, meeting tougher FDA contamination standards
Small molecule, regulatory, operational, strategic - Read more

THE GOOD
Market Reports

Pitchbook report says China's lead in early-stage drug development will likely persist through 2026
Monoclonal antibody, oncology, strategic, licensing deals - Read more

THE GOOD
Regulatory

NICE recommends Sanofi and Regeneron Pharmaceuticals' Dupixent for COPD patients with elevated eosinophils
Monoclonal antibody, respiratory disease, regulatory, cost reduction - Read more

EU launches FAST-EU pilot to accelerate multinational clinical trial approvals by 30 days
Regulatory, operational, strategic, competitive - Read more [Paywall]

UK MHRA seized 20M illegal drugs worth $61.5M in 2025, including 5,600 GLP-1 injections
GLP-1 receptor agonist, metabolic disease, operational, enforcement - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Arcutis Biotherapeutics, Kowa Pharmaceuticals terminate US marketing partnership for Zoryve after two years
Marketing partnership termination, dermatology, commercialization, topical therapy - Read more

THE BAD
Clinical Trials

Genmab halts enrollment for GEN1286 EGFR/c-Met targeting drug in Ph1/2 advanced solid tumors trial
Antibody-drug conjugate, cancer, bispecific antibody, solid tumors, EGFR target, c-Met target - Read more

THE BAD
Fundraises

Gimv exits life sciences investing to focus on consumer, healthcare, smart industries and sustainable cities platforms
Portfolio divestment, strategic, financial, operational - Read more

THE BAD
Investments

AstraZeneca keeps $273M UK Cambridge research site investment paused despite submitting new planning application
Research and development, strategic, operational, major transaction - Read more

THE BAD
Layoffs

Catalent moves to close European cell therapy manufacturing hub in Belgium, affecting 150 workers
Cell therapy, operational, strategic, cost reduction - Read more

THE UGLY
Lawsuits

Ex-CytoDyn CEO sentenced to 30 months prison, $5.3M restitution for investor fraud scheme
Monoclonal antibody, infectious disease, financial, regulatory - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here